Skip to content
Evigrade
ModerateVitamin K antagonist anticoagulants×HMG-CoA reductase inhibitors (statins)

Updated · Methodology

Mechanism

Acenocoumarol is a coumarin derivative and vitamin K antagonist. The Spanish acenocoumarol SmPCs, both the originator and a generic, list simvastatin among statins that can potentiate its anticoagulant effect (acenocoumarol summaries of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The documents do not say how simvastatin produces this effect (AEMPS). According to the simvastatin labels, in two clinical studies simvastatin 20–40 mg a day modestly potentiated the effect of coumarin anticoagulants. The international normalised ratio (INR) rose from 1.7 to 1.8 in healthy volunteers and from 2.6 to 3.4 in patients with high cholesterol (simvastatin SmPC, AEMPS; simvastatin prescribing information, US Food and Drug Administration, FDA). The Spanish simvastatin SmPC also mentions rare cases of increased INR. In people not taking anticoagulants, simvastatin treatment has not been associated with bleeding or changes in prothrombin time (simvastatin SmPC, AEMPS).

Symptoms

According to the US simvastatin label, there are post-marketing reports of clinically evident bleeding or increased international normalised ratio (INR) in people taking statins together with warfarin (simvastatin prescribing information, US Food and Drug Administration, FDA). Acenocoumarol can cause serious or fatal bleeding, including haemorrhagic shock. The risk is higher with an INR above 4.0, at age 65 or older and with concomitant treatment (acenocoumarol summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). With excess acenocoumarol, the most frequent signs are bleeding into the skin and blood in the urine. Other signs include bruising, gastrointestinal, uterine, nose and gum bleeding, vomiting blood and bleeding into joints, as well as fast heartbeat, low blood pressure, nausea, vomiting, diarrhoea and abdominal pain (acenocoumarol SmPC, AEMPS).

Management

No document contraindicates or prohibits this combination, but coagulation is monitored when simvastatin is started. In people taking a coumarin anticoagulant, measure the prothrombin time and the international normalised ratio (INR) before starting simvastatin and frequently enough early in treatment to make sure there is no significant change. Once the value is stable, check it at the intervals usual for the anticoagulant (simvastatin summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS; simvastatin prescribing information, US Food and Drug Administration, FDA). Repeat the same steps if the simvastatin dose is changed or simvastatin is stopped (simvastatin SmPC and prescribing information, AEMPS and FDA). The acenocoumarol SmPCs ask for close and frequent coagulation checks, for example twice a week, both when simvastatin is added and when it is stopped (acenocoumarol SmPCs, AEMPS). With an INR of 4.5–10 and no significant bleeding, interrupt acenocoumarol. With an INR above 10, interrupt it and give 1–5 mg of vitamin K1 by mouth. In significant bleeding, interrupt it and give 5–10 mg of vitamin K1 intravenously very slowly, no faster than 1 mg per minute (acenocoumarol SmPC, AEMPS).

Your whole list in one report

Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email

Add more drugs

Medicine list: everything you take in one place →

Sources

Other interactions with Acenocoumarol

Other interactions with Simvastatin